# Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

> **NCT01476787** · PHASE3 · COMPLETED · sponsor: **Celgene** · enrollment: 1030 (actual)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Lenalidomide
- **DRUG:** Rituximab-CHOP
- **DRUG:** Rituximab-CVP
- **DRUG:** Rituximab-Bendamustine

## Key facts

- **NCT ID:** NCT01476787
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12-29
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-04-30
- **Target enrollment:** 1030 (ACTUAL)
- **Last updated:** 2025-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01476787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01476787, "Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01476787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*